A scheme of the treatment regime beginning at the age of 90 days with pump replacement at the age of 120 days. Timing of open‐field tests is also indicated.Activity levels were measured in a 10‐min open‐field test. Example of tracks of median mice from each group: control mice, SOD1 G93A mice treated with vehicle‐TAT and SOD1 G93A mice treated with P110 (3 mg/kg/day). Circles indicate starting position of the animal during the test.Ambulatory distance, time, episodes, resting time, latency toward center of the chamber, number of center zone entries, and jump counts were analyzed using activity chamber after 10 days of treatment with vehicle‐TAT or P110 at 3 mg/kg/day in G93A SOD1 mice. Grip strength test was carried out to assess the on muscular degeneration after 24 days of treatment.PCA of the entire behavioral data shows behavioral separation between the three groups after treatment with vehicle‐TAT or P110 at 3 mg/kg/day in G93A SOD1 mice. Eigenvectors 1 & 2 represent the values principal components (PC) 1 and 2 for all the behavioral endpoints analyzed.Data information: An experimenter who was blind to genotypes and drug groups conducted all the behavior and survival studies. (C) Mean, standard deviation, and P‐values are shown. (C and D) n = 7 for WT mice; n = 7 for G93A ALS mice + TAT; n = 14 for G93A ALS mice + P110; probability by one‐way ANOVA (with uncorrected Fisher's LSD post hoc test).